Request Demo
Last update 28 May 2025
Docetaxel albumin bound
Last update 28 May 2025
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms Albumin-bound docetaxel, Nab-docetaxel, ABI-008 + [4] |
Target |
Action inhibitors |
Mechanism Tubulin inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (United States) |
Login to view timeline
Related
24
Clinical Trials associated with Docetaxel albumin boundNCT06947291
A Multicenter, Open-label, Phase II Clinical Study to Evaluate the Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors With MET Overexpression and/or Amplification
NCT06747338
A Randomized, Controlled, Open-label, Multicenter, Phase III Clinical Trial to Compare the Efficacy and Safety of KN026 Combined With HB1801 ± Carboplatin Versus Trastuzumab Combined With Pertuzumab and Docetaxel ± Carboplatin in Neoadjuvant Treatment of Early or Locally Advanced HER2-positive Breast Cancer.
CTR20244675
KN026联合HB1801±卡铂对比曲妥珠单抗联合帕妥珠单抗、多西他赛±卡铂新辅助治疗早期或局部晚期HER2阳性乳腺癌的有效性和安全性的随机、对照、开放、多中心、Ⅲ期临床研究
[Translation] A randomized, controlled, open, multicenter, phase III clinical study on the efficacy and safety of KN026 combined with HB1801±carboplatin versus trastuzumab combined with pertuzumab and docetaxel±carboplatin in the neoadjuvant treatment of early or locally advanced HER2-positive breast cancer
100 Clinical Results associated with Docetaxel albumin bound
Login to view more data
100 Translational Medicine associated with Docetaxel albumin bound
Login to view more data
100 Patents (Medical) associated with Docetaxel albumin bound
Login to view more data
100 Deals associated with Docetaxel albumin bound
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Pancreatic Cancer | Phase 3 | - | 12 Aug 2024 | |
| Pancreatic Adenoma | Phase 3 | China | 29 Jul 2024 | |
| Squamous non-small cell lung cancer | Phase 3 | - | 01 May 2024 | |
| Gastroesophageal junction adenocarcinoma | Phase 3 | China | 15 Mar 2024 | |
| stomach adenocarcinoma | Phase 3 | China | 15 Mar 2024 | |
| Stomach Cancer | Phase 3 | China | 27 Feb 2024 | |
| HER2 Positive Breast Cancer | Phase 3 | - | 01 Jul 2023 | |
| Advanced gastric carcinoma | Phase 2 | China | 28 Apr 2025 | |
| Advanced Malignant Solid Neoplasm | Phase 2 | China | 28 Apr 2025 | |
| c-Met positive non-small cell lung cancer | Phase 2 | - | 01 Jul 2024 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 2 | 128 | yvljsuwsfv(rifolrquzl) = raesbflhlg pnavmaodun (ifdylycxwt, 2.8 - 4.2) View more | Positive | 23 Jan 2025 | |||
yvljsuwsfv(rifolrquzl) = zxyimbhdiu pnavmaodun (ifdylycxwt, 1.8 - 3.0) View more | |||||||
NCT05705635 (ASCO2024) Manual  | Phase 2 | 125 | HB1801 (albumin-bound docetaxel) | lnyxfepwcn(kkohgsmytg) = zoeggmrrae qdszaczvlf (krxshmpnyv, 12.88 - 39.54) View more | Positive | 24 May 2024 | |
docetaxel (Taxotere) | lnyxfepwcn(kkohgsmytg) = utcgxuuacg qdszaczvlf (krxshmpnyv, 6.20 - 28.31) View more | ||||||
NCT04931823 (ASCO2024) Manual | Phase 1 | 34 | dwccysxqmk(ervvruhelk) = xbojibzykc zkqwlxmama (ybscnqcdcq ) View more | Positive | 24 May 2024 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free